{{Chembox
| ImageFile = Nemonoxacin structure.svg
| ImageSize = 220px
| IUPACName = 7-[(3S,5S)-3-Amino-5-methyl-1-piperidinyl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
| OtherNames =
|Section1={{Chembox Identifiers
| CASNo =
| PubChem = 11993740
| ChemSpiderID = 10166207
| SMILES = C[C@H]1C[C@H](N)CN(C1)c2ccc3c(c2OC)n(C4CC4)cc(c3=O)C(=O)O
| InChI = 1/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
| InChIKey = AVPQPGFLVZTJOR-RYUDHWBXBZ
| StdInChI = 1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
| StdInChIKey = AVPQPGFLVZTJOR-RYUDHWBXSA-N
  }}
|Section2={{Chembox Properties
| C=20 | H=25 | N=3 |O=4
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = J01
| ATCCode_suffix = MB08
 }}
}}
'''奈諾沙星'''（Nemonoxacin），商品名'''太捷信'''（Taigexyn）是一種非氟{{tsl|en|Quinolone antibiotic|喹諾酮類抗細菌藥}}<ref>{{cite journal|pmid=22650326|year=2012|author1=Guo|first1=B|title=Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses|journal=Clinical Drug Investigation|volume=32|issue=7|pages=475–86|last2=Wu|first2=X|last3=Zhang|first3=Y|last4=Shi|first4=Y|last5=Yu|first5=J|last6=Cao|first6=G|last7=Zhang|first7=J|doi=10.2165/11632780-000000000-00000}}</ref>。本品的抗菌機轉與其他氟喹諾酮（fluouroquinolones）相同，皆是抑制細菌的[[DNA旋转酶|DNA旋转酶]]，抑制細菌DNA的合成及複製，以及細胞分裂。本品目前已經完成台灣、中國<ref>{{Cite journal|title=Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial|url=https://www.sciencedirect.com/science/article/pii/S1684118217301512|date=2017-08-02|journal=Journal of Microbiology, Immunology and Infection|doi=10.1016/j.jmii.2017.07.011|language=en|issn=1684-1182}}</ref>、俄羅斯等地之三期臨床試驗，並完成美國第二期臨床試驗，正進行第三期臨床試驗<ref>{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT02205112|title=A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP - Full Text View - ClinicalTrials.gov|publisher=}}</ref>。[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）已授予本品{{tsl|en|qualified infectious disease product|合格感染性疾病產品資格}}（QIDP）及{{tsl|en|Fast track (FDA)|快速審查 (FDA)|快速審查}}資格，預期將應用於{{tsl|en|community-acquired bacterial pneumonia|社區性肺炎}}及{{tsl|en|acute bacterial skin and skin-structure infection|急性細菌性皮膚與皮膚組織感染}}<ref>{{cite web|url=http://www.news-medical.net/news/20131223/FDA-grants-QIDP-and-Fast-Track-designations-to-TaiGens-nemonoxacin.aspx|title=FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin|date=23 December 2013|publisher=}}</ref>。截至2018年底，本品已授權與台灣、中國、俄羅斯等32國家<ref>{{cite web|url=http://www.news-medical.net/news/20151216/TaiGen-releases-Taigexyn-(nemonoxacin)-capsules-in-Taiwan.aspx|title=TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan|date=16 December 2015|publisher=}}</ref><ref>{{cite web|url=http://www.prnewswire.com/news-releases/taigen-biotechnology-out-licenses-taigexyn-nemonoxacin-to-productos-cientificos-for-the-latin-american-market-300318179.html|title=TaiGen Biotechnology Out-Licenses Taigexyn® (Nemonoxacin) to Productos Científicos for the Latin American Market|first=TaiGen|last=Biotechnology|publisher=}}</ref>，並已在中國上市銷售。

== 適用範圍 ==
本品為廣譜性抗生素，藥效潛能較同屬喹諾酮類抗細菌藥的[[左氧氟沙星|左氧氟沙星]]和[[莫西沙星|莫西沙星]]為佳<ref>{{cite journal|title=Pharmacokinetics and Pharmacodynamics of Nemonoxacin against Streptococcus pneumoniae in an in Vitro Infection Model|first1=W|last2=Chen|first2=Y. C.|journal=Antimicrobial Agents and Chemotherapy|issue=7|doi=10.1128/AAC.01098-12|year=2013|volume=57|pages=2942–2947|pmc=3697386|pmid=23587953|last3=Cao|first3=Y. R.|last4=Liu|first4=X. F.|last5=Huang|first5=J|last6=Hu|first6=J. L.|last7=Zhao|first7=M|last8=Guo|first8=Q. L.|last9=Zhang|first9=S. J.|author1=Liang|last10=Wu|first10=X. J.|last11=Zhu|first11=D. M.|last12=Zhang|first12=Y. Y.|last13=Zhang|first13=J}}</ref>，可對抗多種[[革蘭氏陽性菌|革蘭氏陽性菌]]、[[革兰氏阴性菌|革兰氏阴性菌]]、非典型感染菌等。本品的特色為能對抗多種抗藥性極強的病原體，如[[耐甲氧西林金黄色葡萄球菌|耐甲氧西林金黄色葡萄球菌]]（MRSA）、抗喹諾酮之耐甲氧西林金黄色葡萄球菌（QR-MRSA）、抗萬古黴素金黄色葡萄球菌（VRSA）<ref>{{cite journal | author = Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH | year = 2010 | title = Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates | url = | journal = Antimicrob. Agents Chemother. | volume = 54 | issue = | pages = 1338–1342 | doi=10.1128/aac.01197-09| pmc = 2825994}}</ref><ref>{{cite journal|title=In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates|author=Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG|url=|journal=Antimicrob. Agents Chemother.|issue=|doi=10.1128/aac.00078-09|year=2009|volume=53|pages=4915–4920|pmc=2772340}}</ref>、多重抗藥性肺炎鏈球菌（MDRSP）、{{tsl|en|Clostridium difficile (bacteria)|困難腸梭菌|}}（''C.difficile''）<ref>{{cite journal|title=Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: A Multicenter Study in Taiwan|first1=C. H.|last2=Ko|first2=W. C.|journal=Antimicrobial Agents and Chemotherapy|issue=7|doi=10.1128/AAC.00191-12|year=2012|volume=56|pages=3943–3949|pmc=3393409|pmid=22508299|last3=Lu|first3=J. J.|last4=Hsueh|first4=P. R.|author1=Liao}}</ref>，以及抗盤尼西林肺炎鏈球菌（PRSP）等。

本品對於部分革蘭氏陰性菌的效用較弱，例如[[大腸桿菌|大腸桿菌]]、''{{tsl|en|Proteus mirabilis||Proteus mirabilis}}''，及[[綠膿桿菌|綠膿桿菌]]等等<ref>{{cite journal | author = van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, Ho ML, Chang LW, Chung DT, Chang YT, King CH, Hsu MC | year = 2010 | title = Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia | url = | journal = Antimicrob. Agents Chemother. | volume = 54 | issue = | pages = 4098–4106 | doi=10.1128/aac.00295-10| pmc = 2944601}}</ref>。

== 歷史 ==
本品由[[宝洁|寶鹼]]（P&G）醫藥部門研發。2004年，台灣[[太景生技公司|太景生技公司]]取得授權，並自Ia期試驗後接手研發。

==參考文獻==
{{reflist}}

{{QuinoloneAntiBiotics}}

[[Category:环丙基化合物|Category:环丙基化合物]]
[[Category:哌啶|Category:哌啶]]
[[Category:喹诺酮抗生素|Category:喹诺酮抗生素]]
[[Category:羧酸|Category:羧酸]]
[[Category:芳香醚|Category:芳香醚]]